Merit Medical Systems Acquires PENTAX Medical's C2 CryoBalloon Device and Associated Technologies
Acquisition Announcement: Merit Medical Systems, Inc. has agreed to acquire the C2 CryoBalloon device and related technology from Pentax of America, Inc. for $22 million, with the transaction expected to close in Q4 2025.
Strategic Integration and Financial Impact: The acquisition aims to enhance Merit's Endoscopy portfolio and is projected to generate $6 million to $8 million in revenue for 2026, while initially being dilutive to non-GAAP net income and earnings per share.
Trade with 70% Backtested Accuracy
Analyst Views on MMSI
About MMSI
About the author
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Reaction: While specific stocks are not mentioned, analyst rating changes typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: Investors considering purchasing MMSI stock should pay attention to analysts' opinions to make more informed investment decisions, especially amid increasing market uncertainty.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a comprehensive market perspective and data support.
Wall Street's Latest Rating Changes Overview
- Amazon Downgrade: DA Davidson downgraded Amazon from Buy to Neutral, citing concerns that Amazon Web Services (AWS) is losing market share amid competition from Microsoft and Google, indicating a potential need for increased investment to regain its leading position in the cloud computing sector.
- Merit Medical Initiation: BTIG initiated coverage on Merit Medical with a Buy rating, highlighting its comprehensive product portfolio used across various interventional procedures, which underscores the company's high-quality positioning and growth potential in the medical device market.
- JBS Buy Rating: UBS initiated coverage on Brazilian meat company JBS with a Buy rating and a price target of $19.5 per share, implying a 23% upside, reflecting market confidence in its re-rating and potential stock price appreciation.
- Vistra Upgrade: Goldman Sachs upgraded Vistra from Neutral to Buy, projecting a potential EBITDA increase of 3-9% by 2028, indicating investor optimism regarding its future profitability and growth prospects in the nuclear energy sector.
Merit Medical (MMSI) Receives Upgrade to Buy: Implications for the Stock
Merit Medical Upgrade: Merit Medical (MMSI) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.
Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.
Earnings Estimates: Analysts have raised their earnings estimates for Merit Medical, with the Zacks Consensus Estimate increasing by 0.1% over the past three months, suggesting an improvement in the company's underlying business.
Investment Opportunity: The upgrade places Merit Medical in the top 20% of Zacks-covered stocks, indicating potential for market-beating returns, making it an attractive investment opportunity for investors.
Options Trading for Merit Medical Systems (MMSI) in the First Week of July 2026
Put Contract Overview: The $85.00 put contract has a bid of $6.90, allowing investors to buy MMSI shares at an effective cost of $78.10, which is attractive compared to the current price of $85.81. There is a 59% chance the contract may expire worthless, offering an 8.12% return on cash commitment.
Call Contract Overview: The $90.00 call contract has a bid of $5.70, enabling investors to sell MMSI shares at that price, potentially yielding an 11.53% return if exercised. There is a 50% chance this contract may also expire worthless, providing a 6.64% additional return if it does.
Volatility Insights: The implied volatility for the put contract is 35%, while the call contract has an implied volatility of 31%. The actual trailing twelve-month volatility is calculated at 30%.
YieldBoost Concept: Both put and call contracts offer a "YieldBoost," with the put providing a 12.45% annualized return if it expires worthless, and the call offering a 10.19% annualized return under similar conditions.
Barrington Research Reaffirms Outperform Rating for Merit Medical Systems with $106 Price Target
Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders make informed decisions.
Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.
Merit Medical Unveils 24-Month Efficacy Findings from the Single-Arm AVG Group in the WRAPSODY WAVE Trial
WAVE Trial Findings: The 24-month efficacy results from the WAVE trial showed a target lesion primary patency (TLPP) of 41.7% and an access circuit primary patency (ACPP) of 25.7% for patients treated with the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE).
Device Purpose: The WRAPSODY CIE is designed to restore vascular access in patients on hemodialysis who experience complications such as stenosis or occlusion in their arteriovenous grafts (AVG).
Regulatory Approvals: The WRAPSODY CIE received premarket approval from the FDA in December 2024, followed by approval from Health Canada in April 2025, and it is also available in the European Union and Brazil.
Ongoing Evaluations: Real-world clinical outcomes of the WRAPSODY CIE are being assessed in the WRAP North America Registry and the WRAP Global registry, aiming to enroll up to 250 patients in North America.
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Reaction: While specific stocks are not mentioned, analyst rating changes typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: Investors considering purchasing MMSI stock should pay attention to analysts' opinions to make more informed investment decisions, especially amid increasing market uncertainty.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a comprehensive market perspective and data support.
Wall Street's Latest Rating Changes Overview
- Amazon Downgrade: DA Davidson downgraded Amazon from Buy to Neutral, citing concerns that Amazon Web Services (AWS) is losing market share amid competition from Microsoft and Google, indicating a potential need for increased investment to regain its leading position in the cloud computing sector.
- Merit Medical Initiation: BTIG initiated coverage on Merit Medical with a Buy rating, highlighting its comprehensive product portfolio used across various interventional procedures, which underscores the company's high-quality positioning and growth potential in the medical device market.
- JBS Buy Rating: UBS initiated coverage on Brazilian meat company JBS with a Buy rating and a price target of $19.5 per share, implying a 23% upside, reflecting market confidence in its re-rating and potential stock price appreciation.
- Vistra Upgrade: Goldman Sachs upgraded Vistra from Neutral to Buy, projecting a potential EBITDA increase of 3-9% by 2028, indicating investor optimism regarding its future profitability and growth prospects in the nuclear energy sector.
Merit Medical (MMSI) Receives Upgrade to Buy: Implications for the Stock
Merit Medical Upgrade: Merit Medical (MMSI) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.
Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.
Earnings Estimates: Analysts have raised their earnings estimates for Merit Medical, with the Zacks Consensus Estimate increasing by 0.1% over the past three months, suggesting an improvement in the company's underlying business.
Investment Opportunity: The upgrade places Merit Medical in the top 20% of Zacks-covered stocks, indicating potential for market-beating returns, making it an attractive investment opportunity for investors.
Options Trading for Merit Medical Systems (MMSI) in the First Week of July 2026
Put Contract Overview: The $85.00 put contract has a bid of $6.90, allowing investors to buy MMSI shares at an effective cost of $78.10, which is attractive compared to the current price of $85.81. There is a 59% chance the contract may expire worthless, offering an 8.12% return on cash commitment.
Call Contract Overview: The $90.00 call contract has a bid of $5.70, enabling investors to sell MMSI shares at that price, potentially yielding an 11.53% return if exercised. There is a 50% chance this contract may also expire worthless, providing a 6.64% additional return if it does.
Volatility Insights: The implied volatility for the put contract is 35%, while the call contract has an implied volatility of 31%. The actual trailing twelve-month volatility is calculated at 30%.
YieldBoost Concept: Both put and call contracts offer a "YieldBoost," with the put providing a 12.45% annualized return if it expires worthless, and the call offering a 10.19% annualized return under similar conditions.
Barrington Research Reaffirms Outperform Rating for Merit Medical Systems with $106 Price Target
Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders make informed decisions.
Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.
Merit Medical Unveils 24-Month Efficacy Findings from the Single-Arm AVG Group in the WRAPSODY WAVE Trial
WAVE Trial Findings: The 24-month efficacy results from the WAVE trial showed a target lesion primary patency (TLPP) of 41.7% and an access circuit primary patency (ACPP) of 25.7% for patients treated with the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE).
Device Purpose: The WRAPSODY CIE is designed to restore vascular access in patients on hemodialysis who experience complications such as stenosis or occlusion in their arteriovenous grafts (AVG).
Regulatory Approvals: The WRAPSODY CIE received premarket approval from the FDA in December 2024, followed by approval from Health Canada in April 2025, and it is also available in the European Union and Brazil.
Ongoing Evaluations: Real-world clinical outcomes of the WRAPSODY CIE are being assessed in the WRAP North America Registry and the WRAP Global registry, aiming to enroll up to 250 patients in North America.
